Comprehensive T cell repertoire characterization of non-small cell lung cancer

Alexandre Reuben(The University of Texas MD Anderson Cancer Center), Jiexin Zhang(The University of Texas MD Anderson Cancer Center), Shin‐Heng Chiou(Howard Hughes Medical Institute), Rachel M. Gittelman(Adaptive Biotechnologies (United States)), Jun Li(The University of Texas MD Anderson Cancer Center), Won-Chul Lee(The University of Texas MD Anderson Cancer Center), Junya Fujimoto(The University of Texas MD Anderson Cancer Center), Carmen Behrens(The University of Texas MD Anderson Cancer Center), Xiaoke Liu(The University of Texas MD Anderson Cancer Center), Feng Wang(The University of Texas MD Anderson Cancer Center), Kelly Quek(The University of Texas MD Anderson Cancer Center), Chunlin Wang(iRepertoire (United States)), Farrah Kheradmand(Baylor College of Medicine), Runzhe Chen(The University of Texas MD Anderson Cancer Center), Chi‐Wan Chow(The University of Texas MD Anderson Cancer Center), Heather Lin(The University of Texas MD Anderson Cancer Center), Chantale Bernatchez(The University of Texas MD Anderson Cancer Center), Ali Jalali(The University of Texas MD Anderson Cancer Center), Xin Hu(The University of Texas MD Anderson Cancer Center), Chang‐Jiun Wu(The University of Texas MD Anderson Cancer Center), Agda Karina Eterovic(The University of Texas MD Anderson Cancer Center), Edwin R. Parra(The University of Texas MD Anderson Cancer Center), Erik Yusko(Adaptive Biotechnologies (United States)), Ryan Emerson(Adaptive Biotechnologies (United States)), Sharon Benzeno(Adaptive Biotechnologies (United States)), Marissa Vignali(Adaptive Biotechnologies (United States)), Xifeng Wu(The University of Texas MD Anderson Cancer Center), Yuanqing Ye(The University of Texas MD Anderson Cancer Center), Latasha Little(The University of Texas MD Anderson Cancer Center), Curtis Gumbs(The University of Texas MD Anderson Cancer Center), Xizeng Mao(The University of Texas MD Anderson Cancer Center), Xingzhi Song(The University of Texas MD Anderson Cancer Center), Samantha Tippen(The University of Texas MD Anderson Cancer Center), Rebecca Thornton(The University of Texas MD Anderson Cancer Center), Tina Cascone(The University of Texas MD Anderson Cancer Center), Alexandra Snyder(Adaptive Biotechnologies (United States)), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Roy S. Herbst(Yale Cancer Center), Stephen G. Swisher(The University of Texas MD Anderson Cancer Center), Humam Kadara(The University of Texas MD Anderson Cancer Center), César A. Moran(The University of Texas MD Anderson Cancer Center), Neda Kalhor(The University of Texas MD Anderson Cancer Center), Jianhua Zhang(The University of Texas MD Anderson Cancer Center), Paul Scheet(The University of Texas MD Anderson Cancer Center), Ara A. Vaporciyan(The University of Texas MD Anderson Cancer Center), Boris Sepesi(The University of Texas MD Anderson Cancer Center), Don L. Gibbons(The University of Texas MD Anderson Cancer Center), Harlan Robins(North Seattle College), Patrick Hwu(The University of Texas MD Anderson Cancer Center), John V. Heymach(The University of Texas MD Anderson Cancer Center), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), James P. Allison(The University of Texas MD Anderson Cancer Center), Veera Baladandayuthapani(The University of Texas MD Anderson Cancer Center), J. Jack Lee(The University of Texas MD Anderson Cancer Center), Mark M. Davis(Howard Hughes Medical Institute), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), P. Andrew Futreal(The University of Texas MD Anderson Cancer Center), Jianjun Zhang(The University of Texas MD Anderson Cancer Center)
Nature Communications
January 30, 2020
Cited by 228Open Access
Full Text

Abstract

Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better understanding of the T cells in the lungs of patients with NSCLC. Here, we report T cell repertoire analysis in a cohort of 236 early-stage NSCLC patients. T cell repertoire attributes are associated with clinicopathologic features, mutational and immune landscape. A considerable proportion of the most prevalent T cells in tumors are also prevalent in the uninvolved tumor-adjacent lungs and appear specific to shared background mutations or viral infections. Patients with higher T cell repertoire homology between the tumor and uninvolved tumor-adjacent lung, suggesting a less tumor-focused T cell response, exhibit inferior survival. These findings indicate that a concise understanding of antigens and T cells in NSCLC is needed to improve therapeutic efficacy and reduce toxicity with immunotherapy, particularly adoptive T cell therapy.


Related Papers